- Home
- NERV vs CYCU Comparison
NERV vs CYCU Comparison
Compare NERV & CYCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- CYCU
- Stock Information
- Founded
- NERV 2007
- CYCU N/A
- Country
- NERV United States
- CYCU United States
- Employees
- NERV N/A
- CYCU N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- CYCU
- Sector
- NERV Health Care
- CYCU
- Exchange
- NERV Nasdaq
- CYCU Nasdaq
- Market Cap
- NERV 12.0M
- CYCU 13.1M
- IPO Year
- NERV 2014
- CYCU N/A
- Fundamental
- Price
- NERV $2.25
- CYCU $0.28
- Analyst Decision
- NERV Hold
- CYCU
- Analyst Count
- NERV 1
- CYCU 0
- Target Price
- NERV $5.00
- CYCU N/A
- AVG Volume (30 Days)
- NERV 35.1K
- CYCU 3.5M
- Earning Date
- NERV 08-14-2025
- CYCU 08-13-2025
- Dividend Yield
- NERV N/A
- CYCU N/A
- EPS Growth
- NERV N/A
- CYCU N/A
- EPS
- NERV 1.48
- CYCU N/A
- Revenue
- NERV N/A
- CYCU $17,398,680.00
- Revenue This Year
- NERV N/A
- CYCU N/A
- Revenue Next Year
- NERV N/A
- CYCU N/A
- P/E Ratio
- NERV $1.52
- CYCU N/A
- Revenue Growth
- NERV N/A
- CYCU N/A
- 52 Week Low
- NERV $1.15
- CYCU $0.26
- 52 Week High
- NERV $3.00
- CYCU $10.99
- Technical
- Relative Strength Index (RSI)
- NERV 69.92
- CYCU N/A
- Support Level
- NERV $1.79
- CYCU N/A
- Resistance Level
- NERV $1.81
- CYCU N/A
- Average True Range (ATR)
- NERV 0.10
- CYCU 0.00
- MACD
- NERV 0.01
- CYCU 0.00
- Stochastic Oscillator
- NERV 76.56
- CYCU 0.00
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).